InvestSMART

Atomo Diagnostics Limited (ASX: AT1) - Share Price

- Current share price for AT1 : $0.017

Atomo Diagnostics Limited (AT1), an ASX-listed company, is a Company that is engaged in development and sale of medical devices.

AT1 General Information +

ASX Code AT1
Website http://www.atomodiagnostics.com
Industry/Sector Health Care Equipment
Market Cap ($M) 15
AT1 Share Price $0.017
Day High $0.017
Day Low $0.016
Last Close $0.017
AT1 Share Price Movement - ( No change )
Prices as at 16:40, 26 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Atomo Diagnostics Limited (AT1) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Atomo Diagnostics Limited (AT1) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Atomo Diagnostics Limited (AT1) price-sensitive announcements

AT1 - Share Purchase Plan Results
Atomo Diagnostics Limited announced the results of its Share Purchase Plan (SPP) which clo
Atomo Diagnostics Limited (AT1)
15 May 2026 | 11:06 AM
AT1 - Quarterly Activities/Appendix 4C Cash Flow Report
Atomo Diagnostics Limited, trading on the ASX as AT1, has reported its financial and opera
Atomo Diagnostics Limited (AT1)
28 Apr 2026 | 9:53 AM
AT1 - Response to ASX Aware Letter
Atomo Diagnostics Limited responded to an ASX Aware Letter concerning its recent announcem
Atomo Diagnostics Limited (AT1)
17 Apr 2026 | 10:23 AM
AT1 - Atomo Completes Capital Raise
Atomo Diagnostics Limited, an Australian medical device company, has completed a capital r
Atomo Diagnostics Limited (AT1)
30 Mar 2026 | 9:55 AM

Atomo Diagnostics Limited (AT1) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
Atomo Diagnostics Limited (AT1)
ORDINARY FULLY PAID
 Health Care $15 Change in substantial holding 29 May 2026 7:11PM $0.021 $0.017 fallen by 19.05%
Atomo Diagnostics Limited (AT1)
ORDINARY FULLY PAID
 Health Care $15 Notification regarding unquoted securities - AT1 15 May 2026 11:23AM $0.022 $0.017 fallen by 22.73%
Atomo Diagnostics Limited (AT1)
ORDINARY FULLY PAID
 Health Care $15 Application for quotation of securities - AT1 15 May 2026 11:09AM $0.022 $0.017 fallen by 22.73%
Atomo Diagnostics Limited (AT1)
ORDINARY FULLY PAID
 Health Care $15 Share Purchase Plan Results 15 May 2026 11:06AM $0.022 $0.017 fallen by 22.73%
Atomo Diagnostics Limited (AT1)
ORDINARY FULLY PAID
 Health Care $15 Quarterly Activities/Appendix 4C Cash Flow Report 28 Apr 2026 9:53AM $0.027 $0.017 fallen by 37.04%
Atomo Diagnostics Limited (AT1)
ORDINARY FULLY PAID
 Health Care $15 Investor Webinar Presentation 23 Apr 2026 9:09AM $0.027 $0.017 fallen by 37.04%

AT1 Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2025A -$4.97 -$0.80 -19.00% 0.00 0.00 0.00% 0.0%
2024A -$6.05 -$1.00 -45.40% 0.00 0.00 0.00% 0.0%
2023A -$9.96 -$1.70 74.00% 0.00 0.00 0.00% 0.0%

AT1 Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2023 A 2024 A 2025 A 2023 A 2024 A 2025 A 2023 A 2024 A 2025 A
Atomo Diagnostics Limited (AT1) $15M -0.1895 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Cochlear Limited (COH) $7,622M 0.0171 -0.1883 0.0862 19.4760 23.9938 22.0906 3.69% 2.97% 3.17%
Fisher & Paykel Healthcare Corporation Limited (FPH) $18,517M 0.1388 0.1359 0.1882 47.6788 41.9728 35.3238 1.38% 1.47% 1.66%
ResMed Inc. (RMD) $16,678M 0.3087 9.7634 0.0805 200.8253 18.6581 17.2679 1.15% 1.20% 1.27%

AT1 Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 1.81 0.00
Market 0.29 13.30 1.15 0.66
Sector 0.65 22.30 1.60 2.80

AT1 Directors

Name Position Start Date
Mr John Michael Kelly Chief Executive Officer, Managing Director, Interim Chairman 1 Apr 2010
Dr Cheri Louise Walker Non-Executive Director 15 Nov 2022
Mr Anthony May Non-Executive Director 2 May 2025
Mr Patrick Cook Non-Executive Director 2 May 2025

Atomo Diagnostics Limited (AT1) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
27 Jun 2025 KELLY, John Issued Direct Shares 1,621,622 $0.018 $30,000.000
27 Jun 2025 MAY, Anthony Issued Indirect Shares 540,541 $0.018 $10,000.000
27 Jun 2025 COOK, Patrick Issued Indirect Shares 540,541 $0.018 $10,000.000

See all changes in directors' interest & trades for Atomo Diagnostics Limited (AT1) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

AT1 Management

Name Position
Chandra Sukumar Chief Operating Officer
Mathew Leslie Watkins Company Secretary

AT1 Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Atomo Diagnostics Limited (AT1). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
116,922,671 (14.43%) GZ Family Holdings Pty Ltd
74,111,870 (9.15%) John Kelly
64,392,433 (7.95%) Mr Xiaoyi Lin
61,570,716 (7.60%) Global Health Investment Fund LLC

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.